In support of the role of IL-8 as factor of resistance to bevacizumab in metastatic colorectal cancer patients, a better clinical outcome was reported when IL-8 baseline levels were lower [30, 31]. The gene discussed is CXCL8; the disease is metastatic colorectal cancer.